Stockscreener 앱 받기
8.62
0.69%
-0.06
시간 외 거래:
8.78
0.16
+1.86%
전일 마감가:
$8.68
열려 있는:
$8.75
하루 거래량:
390.15K
Relative Volume:
0.79
시가총액:
$245.01M
수익:
$67.22M
순이익/손실:
$-65.78M
주가수익비율:
-3.6117
EPS:
-2.3867
순현금흐름:
$-79.02M
1주 성능:
+1.41%
1개월 성능:
+29.04%
6개월 성능:
-60.04%
1년 성능:
-18.45%
1일 변동 폭
$8.61
$8.925
1주일 범위
$8.1001
$8.925
52주 변동 폭
$5.85
$24.17
Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile
명칭
Arcturus Therapeutics Holdings Inc
전화
(858) 900-2660
주소
10285 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Compare ARCT vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ARCT
Arcturus Therapeutics Holdings Inc
|
8.62 | 246.71M | 67.22M | -65.78M | -79.02M | -2.3867 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-18 | 개시 | B. Riley Securities | Buy |
| 2026-01-23 | 개시 | Roth Capital | Buy |
| 2025-10-24 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-10-23 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-10-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2025-09-04 | 재개 | H.C. Wainwright | Buy |
| 2025-05-28 | 개시 | Scotiabank | Sector Outperform |
| 2025-01-28 | 개시 | BTIG Research | Buy |
| 2024-08-12 | 개시 | Leerink Partners | Outperform |
| 2023-12-13 | 개시 | Canaccord Genuity | Buy |
| 2023-07-24 | 개시 | William Blair | Outperform |
| 2023-05-11 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2022-11-14 | 재개 | Wells Fargo | Overweight |
| 2022-11-10 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2022-11-03 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-11-02 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2022-08-10 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2022-07-19 | 재개 | Cantor Fitzgerald | Overweight |
| 2022-05-11 | 업그레이드 | Robert W. Baird | Underperform → Neutral |
| 2022-04-21 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-01-31 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2021-08-12 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2021-08-11 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-08-10 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2021-07-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-06-25 | 재개 | Goldman | Neutral |
| 2021-06-21 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2021-06-04 | 재개 | Robert W. Baird | Neutral |
| 2021-02-17 | 다운그레이드 | B. Riley Securities | Neutral → Sell |
| 2021-01-19 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2021-01-15 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2021-01-07 | 개시 | Wells Fargo | Overweight |
| 2020-12-29 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2020-12-29 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-12-29 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-12-29 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-12-23 | 다운그레이드 | ROTH Capital | Buy → Sell |
| 2020-12-08 | 재확인 | B. Riley Securities | Buy |
| 2020-12-07 | 재확인 | B. Riley Securities | Buy |
| 2020-10-26 | 개시 | Barclays | Overweight |
| 2020-10-06 | 개시 | Citigroup | Buy |
| 2020-08-26 | 개시 | Piper Sandler | Overweight |
| 2020-07-30 | 재개 | ROTH Capital | Buy |
| 2020-07-16 | 개시 | Raymond James | Outperform |
| 2020-07-13 | 개시 | B. Riley FBR | Buy |
| 2020-06-09 | 다운그레이드 | WBB Securities | Buy → Hold |
| 2020-02-11 | 개시 | Robert W. Baird | Outperform |
| 2020-02-07 | 개시 | Guggenheim | Buy |
| 2020-02-06 | 개시 | Guggenheim | Buy |
| 2019-04-05 | 개시 | H.C. Wainwright | Buy |
| 2018-09-20 | 업그레이드 | WBB Securities | Buy → Strong Buy |
| 2018-01-22 | 개시 | Chardan Capital Markets | Buy |
모두보기
Arcturus Therapeutics Holdings Inc 주식(ARCT)의 최신 뉴스
(ARCT) and the Role of Price-Sensitive Allocations - Stock Traders Daily
ARCT Stock Price, Quote & Chart | ARCTURUS THERAPEUTICS HOLDIN (NASDAQ:ARCT) - ChartMill
Published on: 2026-04-10 06:58:22 - baoquankhu1.vn
HC Wainwright & Co. Downgrades Arcturus Therapeutics Holdings (ARCT) - MSN
Responsive Playbooks and the ARCT Inflection - Stock Traders Daily
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2025 earnings call transcript - MSN
Hennion & Walsh Asset Management Inc. Purchases 161,910 Shares of Arcturus Therapeutics Holdings Inc. $ARCT - marketbeat.com
ARCT SEC FilingsArcturus Therape 10-K, 10-Q, 8-K Forms - Stock Titan
Arcturus Therapeutics (NASDAQ:ARCT) Share Price Passes Below 200 Day Moving AverageShould You Sell? - MarketBeat
Arcturus Therapeutics features Chief Medical Officer in The Bonnell Foundation podcast discussion - Traders Union
Arcturus Therapeutics Holdings (ARCT) price target decreased by 27.17% to 25.78 - MSN
BTIG Maintains Arcturus Therapeutics Holdings (ARCT) Buy Recommendation - MSN
Cathie Wood’s ARK sells Nvidia stock, buys Arcturus Therapeutics By Investing.com - Investing.com UK
Cathie Wood’s ARK sells Nvidia stock, buys Arcturus Therapeutics - Investing.com
ARCT.O - Reuters
Roth MKM Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Vanguard disaggregates holdings; reports 0 shares — Arcturus (ARCT) - Stock Titan
New Highs: Is Arcturus Therapeutics Holdings Inc forming a breakout pattern2026 Historical Comparison & Accurate Buy Signal Notifications - baoquankhu1.vn
Aug Setups: How is Arcturus Therapeutics Holdings Inc managing supply chain issuesMarket Activity Report & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Understanding the Setup: (ARCT) and Scalable Risk - Stock Traders Daily
Arcturus Therapeutics Refocuses on Rare Disease mRNA Pipeline After COVID Vaccine Success at ROTH Conf - MarketBeat
Arcturus Therapeutics at the 38th Annual Roth Conference: Strategic Shift to Rare Diseases - Investing.com Canada
These Are the Only 3 Stocks That Cathie Wood Bought Last Week - The Motley Fool
Arcturus Therapeutics stock plunges 50% after weak cystic fibrosis trial data - MSN
This Rubrik Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday - Benzinga
Arcturus Therapeutics (NASDAQ:ARCT) Stock Rating Upgraded by B. Riley Financial - marketbeat.com
This BP Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Friday - Benzinga
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Average Recommendation of "Moderate Buy" from Analysts - marketbeat.com
This Xponential Fitness Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday - Benzinga
This Rocket Lab Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - benzinga.com
This Union Pacific Analyst Turns Bullish; Here Are Top 3 Upgrades For Wednesday - Benzinga
B Riley Securities initiates coverage of Arcturus Therapeutics Holdings (ARCT) with buy recommendation - MSN
Cathie Wood’s ARK sells Guardant Health stock, buys Arcturus Therapeutics By Investing.com - Investing.com Canada
Cathie Wood’s ARK sells Guardant Health stock, buys Arcturus Therapeutics - Investing.com
Arcturus Therapeutics (NASDAQ:ARCT) Coverage Initiated at B. Riley Financial - MarketBeat
This Evommune Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
ARCT: B. Riley Securities Initiates Coverage with 'Buy' Rating | - GuruFocus
Arcturus Therapeutics stresses importance of phased clinical trials in drug development - Traders Union
Update Recap: How is Arcturus Therapeutics Holdings Inc managing supply chain issuesWeekly Stock Summary & Short-Term Swing Trade Alerts - baoquankhu1.vn
Can Arcturus Therapeutics Holdings Inc sustain its profitabilityMarket Sentiment Review & Reliable Entry Point Alerts - baoquankhu1.vn
The Technical Signals Behind (ARCT) That Institutions Follow - Stock Traders Daily
Arcturus Therapeutics Teases 12-Week Phase 2 CF Study After Well-Tolerated Inhaled mRNA Dosing - marketbeat.com
Arcturus Therapeutics Holdings Inc (ARCT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):